[HTML][HTML] Multiple myeloma with t (11; 14): unique biology and evolving landscape
Multiple myeloma is characterized by heterogeneity in clinical presentation, response to
treatment, and importantly, patient outcomes. The translocation of chromosomes 11 and 14 [t …
treatment, and importantly, patient outcomes. The translocation of chromosomes 11 and 14 [t …
Genome instability in multiple myeloma: Facts and factors
Simple Summary Multiple myeloma is an incurable blood cancer caused by the malignant
transformation of immunoglobulin-producing plasma cells. The mechanisms leading to the …
transformation of immunoglobulin-producing plasma cells. The mechanisms leading to the …
Implementing a functional precision medicine tumor board for acute myeloid leukemia
We generated ex vivo drug-response and multiomics profiling data for a prospective series
of 252 samples from 186 patients with acute myeloid leukemia (AML). A functional precision …
of 252 samples from 186 patients with acute myeloid leukemia (AML). A functional precision …
[HTML][HTML] Multiple myeloma: the (r) evolution of current therapy and a glance into the future
KC Anderson - Haematologica, 2020 - ncbi.nlm.nih.gov
Over the past 20 years, the regulatory approval of several novel agents to treat multiple
myeloma (MM) has prolonged median patient survival from 3 to 8-10 years. Increased …
myeloma (MM) has prolonged median patient survival from 3 to 8-10 years. Increased …
Patient similarity network of newly diagnosed multiple myeloma identifies patient subgroups with distinct genetic features and clinical implications
The remarkable genetic heterogeneity of multiple myeloma poses a substantial challenge
for proper prognostication and clinical management of patients. Here, we introduce MM …
for proper prognostication and clinical management of patients. Here, we introduce MM …
A systems approach to clinical oncology uses deep phenotyping to deliver personalized care
Cancer encompasses a complex, heterogeneous and dynamic group of diseases that arise
from perturbations to multiple biological networks within the body. A systems biology-based …
from perturbations to multiple biological networks within the body. A systems biology-based …
The future of myeloma precision medicine: integrating the compendium of known drug resistance mechanisms with emerging tumor profiling technologies
Multiple myeloma (MM) is a hematologic malignancy that is considered mostly incurable in
large part due to the inability of standard of care therapies to overcome refractory disease …
large part due to the inability of standard of care therapies to overcome refractory disease …
Myeloma Genome Project Panel is a comprehensive targeted genomics panel for molecular profiling of patients with multiple myeloma
Purpose: We designed a comprehensive multiple myeloma targeted sequencing panel to
identify common genomic abnormalities in a single assay and validated it against known …
identify common genomic abnormalities in a single assay and validated it against known …
A three-gene signature predicts response to selinexor in multiple myeloma
PURPOSE Selinexor is the first selective inhibitor of nuclear export to be approved for the
treatment of relapsed or refractory multiple myeloma (MM). Currently, there are no known …
treatment of relapsed or refractory multiple myeloma (MM). Currently, there are no known …
Outcomes with panobinostat in heavily pretreated multiple myeloma patients
Panobinostat is an oral pan histone-deacetylase inhibitor used in the treatment of relapsed
and refractory multiple myeloma. Previously published studies of panobinostat …
and refractory multiple myeloma. Previously published studies of panobinostat …